miglustat has been researched along with Disease Models, Animal in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (8.33) | 18.2507 |
2000's | 10 (27.78) | 29.6817 |
2010's | 21 (58.33) | 24.3611 |
2020's | 2 (5.56) | 2.80 |
Authors | Studies |
---|---|
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Antipova, V; Holzmann, C; Rolfs, A; Witt, M; Wree, A | 1 |
Günther, R; Holzmann, C; Meyer, A; Rolfs, A; Schmitt, O; Witt, M; Wree, A | 1 |
Boudewyn, LC; Dobrenis, K; Grishchuk, Y; Kuchar, L; Ledvinova, J; Sikora, J; Walkley, SU; Wang, SL | 1 |
Do, HV; Feng, J; Frascella, M; Garcia, A; Gotschall, R; Khanna, R; Lun, Y; Martina, JA; Nair, A; Ponery, AS; Puertollano, R; Raben, N; Ralston, E; Schilling, A; Soska, R; Tuske, S; Valenzano, KJ; Valle, MCD; Xu, S | 1 |
Bräuer, AU; Burstein, C; Engelmann, R; Frank, M; Gläser, A; Gräler, M; Müller-Hilke, B; Neidhardt, J; Neßlauer, AM; Rolfs, A; Witt, M; Wree, A | 1 |
Ikenoya, S; Kitatani, T; Takahashi, S | 1 |
Blank, PS; Cluzeau, CV; Cologna, SM; Dail, MK; Lieberman, AP; Porter, FD; Siebel, S; Toth, CL; Wassif, CA; Yanjanin, NM | 1 |
Frech, MJ; Holzmann, C; Hovakimyan, M; Hübner, R; Lukas, J; Maass, F; Petersen, J; Rolfs, A; Witt, M; Wree, A | 1 |
Haÿ, E; Jacquot, JP; Le Henaff, C; Marie, PJ; Marty, C; Tabary, O; Velard, F | 1 |
Agovino, T; Andria, G; Ascione, S; Danesino, C; De Filippi, P; Della Casa, R; Donati, MA; Fecarotta, S; la Marca, G; Mollica, C; Morandi, LO; Nusco, E; Ombrone, D; Parenti, G; Pasanisi, MB; Pichiecchio, A; Porto, C; Ravaglia, S; Romano, A; Rosa, M; Rossi, B; Sacchini, M | 1 |
Hawlitschka, A; Hovakimyan, M; Lukas, J; Maass, F; Petersen, J; Rolfs, A; Schmitt, O; Witt, M; Wree, A | 1 |
Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F | 1 |
Cardinale, A; Cutarelli, A; D'Arcangelo, G; Frank, C; Grossi, D; Merlo, D; Racaniello, M; Rufini, S; Tancredi, V; Zaratti, A | 1 |
Byers, S; Derrick-Roberts, A; Fletcher, J; Kaidonis, X; Ranieri, E; Sharp, P | 1 |
Grittner, U; Holzmann, C; Rolfs, A; Schlegel, V; Thieme, M; Witt, M; Wree, A | 1 |
Agans, KN; Callahan, MV; Garza, NL; Geisbert, JB; Geisbert, TW; Klose, B; Mire, CE; Qiu, X; Ramstedt, U; Shurtleff, AC; Stuthman, KS; Treston, AM; Van Tongeren, SA; Warfield, KL; Warren, TK; Wells, J; Wong, G | 1 |
Ali, NF; Davidson, CD; Dobrenis, K; Micsenyi, MC; Ory, DS; Renault, S; Stephney, G; Vanier, MT; Walkley, SU | 1 |
Hughes, DA; Pastores, GM | 1 |
Berton, G; Bezzerri, V; Cabrini, G; Cioffi, F; Dechecchi, MC; Gambari, R; Huang, S; Lampronti, I; Mazzi, P; Nicolis, E; Scupoli, MT; Wiszniewski, L | 1 |
Donald, A; Oko, R; van der Spoel, AC; Xu, W | 1 |
Fornfeist, S | 1 |
Igdoura, SA; Venier, RE | 1 |
Hibi, T; Miura, S; Mizushima, T; Nagata, H; Nakashita, M; Suzuki, H; Taki, T; Uehara, K | 1 |
Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM | 1 |
Futerman, AH; Jeyakumar, M; Lloyd-Evans, E; Pelled, D; Platt, FM; Riebeling, C | 1 |
Andersson, U; Butters, TD; Dwek, RA; Heare, T; Jeyakumar, M; Platt, FM | 1 |
Butters, TD; Dwek, RA; Platt, FM | 1 |
Alp, NJ; Butters, TD; Channon, KM; Clarke, K; Dwek, RA; Heare, T; Kulkarni, AB; Platt, FM; Priestman, DA; Qasba, P | 1 |
Itoh, K; Tsuji, D | 1 |
Butters, TD; d'Azzo, A; Dwek, RA; Elliot-Smith, E; Jeyakumar, M; Lloyd-Evans, E; Platt, FM; Smith, DA; Speak, AO; van der Spoel, AC | 1 |
Butters, TD; Dwek, RA; Karlsson, GB; Neises, GR; Platt, FM | 1 |
Butters, TD; Dwek, RA; Neises, GR; Perry, VH; Platt, FM; Proia, RL; Reinkensmeier, G; Townsend, MJ; Winchester, B | 1 |
Chavany, C; Jendoubi, M | 1 |
Butters, TD; Cortina-Borja, M; Dwek, RA; Jeyakumar, M; Norflus, F; Perry, VH; Platt, FM; Proia, RL; Tifft, CJ | 1 |
Somers, KL; Thrall, MA; Walkley, SU; Zervas, M | 1 |
8 review(s) available for miglustat and Disease Models, Animal
Article | Year |
---|---|
[Pharmacological and clinical profiles of miglustat (Brazaves(®)) for the treatment of Niemann-Pick type C disease].
Topics: 1-Deoxynojirimycin; Animals; Calcium; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Glucosyltransferases; Humans; Lysosomes; Mice; Niemann-Pick Disease, Type C | 2013 |
The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.
Topics: 1-Deoxynojirimycin; Animals; Autophagy; Calcium; Cell Membrane; Disease Models, Animal; DNA Mutational Analysis; Endoplasmic Reticulum; Enzyme Inhibitors; Enzyme Replacement Therapy; Gaucher Disease; Genetic Therapy; Glucosylceramidase; Glucosylceramides; Glycolipids; Homeostasis; Humans; Mice; Oxidative Stress; Proteostasis Deficiencies | 2010 |
Miglustat as a therapeutic agent: prospects and caveats.
Topics: 1-Deoxynojirimycin; Animals; Clinical Trials as Topic; Disease Models, Animal; Gangliosides; Gaucher Disease; Humans | 2012 |
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Topics: 1-Deoxynojirimycin; Animals; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Models, Animal; G(M2) Ganglioside; Gangliosides; Glucosylceramides; Glucosyltransferases; Glycosphingolipids; Humans; Lysosomal Storage Diseases; Lysosomes; Mice; Models, Biological; Models, Chemical; Morpholines; Sandhoff Disease; Tay-Sachs Disease; Treatment Outcome | 2002 |
Substrate reduction therapy in mouse models of the glycosphingolipidoses.
Topics: 1-Deoxynojirimycin; Animals; Disease Models, Animal; Enzyme Inhibitors; Mice; Sphingolipidoses; Substrate Specificity | 2003 |
New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Topics: 1-Deoxynojirimycin; Animals; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Gaucher Disease; Glycosphingolipids; Humans; In Vitro Techniques; Lysosomal Storage Diseases; Mice | 2003 |
[Molecular pathogenesis and therapeutic targets of lysosomal diseases].
Topics: 1-Deoxynojirimycin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta-N-Acetylhexosaminidases; Bone Marrow Transplantation; Disease Models, Animal; G(M2) Activator Protein; Genetic Therapy; Humans; Lysosomal Storage Diseases, Nervous System; Mutation | 2007 |
Biology and potential strategies for the treatment of GM2 gangliosidoses.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Animals; beta-N-Acetylhexosaminidases; Bone Marrow Transplantation; Cats; Cell Transplantation; Child; Disease Models, Animal; Dogs; G(M2) Ganglioside; Genetic Therapy; Genetic Vectors; Glycolipids; HIV; Humans; Infant; Lysosomes; Mice; Mice, Knockout; Neurons; Phenotype; Point Mutation; Rats; Sandhoff Disease; Swine; Tay-Sachs Disease; Transplantation, Homologous | 1998 |
28 other study(ies) available for miglustat and Disease Models, Animal
Article | Year |
---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Animals; Cyclodextrins; Disease Models, Animal; Drug Therapy, Combination; Female; Male; Mice; Mice, Inbred BALB C; Niemann-Pick Disease, Type C; Pregnanolone | 2021 |
Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Animals; Apoptosis; beta-Cyclodextrins; Cell Proliferation; Disease Models, Animal; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mutation; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Olfactory Mucosa; Pregnanolone; Proteins | 2017 |
N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.
Topics: 1-Deoxynojirimycin; Animals; Antigens, CD; Cell Count; Cerebellum; Disease Models, Animal; Enzyme Inhibitors; Exploratory Behavior; Gliosis; Lipid Metabolism; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement Disorders; Mucolipidoses; Nerve Tissue Proteins; Psychomotor Performance; Purkinje Cells; Retina; Transient Receptor Potential Channels | 2017 |
Improved efficacy of a next-generation ERT in murine Pompe disease.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Disease Models, Animal; Enzyme Replacement Therapy; Female; Glycogen; Glycogen Storage Disease Type II; Humans; Lysosomes; Male; Mannosephosphates; Mice; Mice, Knockout; Muscle, Skeletal; Rats; Rats, Sprague-Dawley | 2019 |
A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Animals; Cell Separation; Disease Models, Animal; Flow Cytometry; Genotype; Lipid Metabolism; Mice; Niemann-Pick Disease, Type C; Pregnanolone; Spleen | 2019 |
Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.
Topics: 1-Deoxynojirimycin; Adolescent; Alleles; Animals; Biomarkers; Brain; Cerebellum; Cerebral Cortex; Chemokine CCL3; Chemokine CXCL5; Child; Child, Preschool; Complement C3; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Infant; Infant, Newborn; Inflammation; Interleukins; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Niemann-Pick Disease, Type C; Young Adult | 2014 |
Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice.
Topics: 1-Deoxynojirimycin; Animals; Cognition; Cyclodextrins; Disease Models, Animal; Drug Therapy, Combination; Mice; Mice, Knockout; Microscopy, Electron, Transmission; Motor Activity; Neuroprotective Agents; Niemann-Pick Disease, Type C; Pregnanolone | 2013 |
Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis.
Topics: 1-Deoxynojirimycin; Animals; Bone and Bones; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Enzyme Inhibitors; Male; Mice, Inbred CFTR; Mutation; Osteoblasts | 2014 |
A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; alpha-Glucosidases; Animals; Child; Child, Preschool; Disease Models, Animal; Dried Blood Spot Testing; Drug Synergism; Enzyme Replacement Therapy; Enzyme Stability; Female; Glycogen Storage Disease Type II; Glycoside Hydrolase Inhibitors; Humans; Male; Mice; Middle Aged; Young Adult | 2014 |
Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease.
Topics: 1-Deoxynojirimycin; Animals; Cell Count; Cerebellum; Cyclodextrins; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Mice; Nerve Degeneration; Neurons; Niemann-Pick Disease, Type C; Pregnanolone | 2015 |
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Gaucher Disease; Glycoside Hydrolase Inhibitors; Histocompatibility Antigens; Inositol; L-Lactate Dehydrogenase; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mitochondrial Diseases; Neurons; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2015 |
Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease.
Topics: 1-Deoxynojirimycin; Animals; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Hippocampus; Mice; Neuronal Plasticity; Niemann-Pick Disease, Type C; Phosphorylation; Synapses | 2016 |
N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Animals; Brain; Chemokine CCL3; Disease Models, Animal; Fear; Gangliosides; Glucosyltransferases; Glycoside Hydrolase Inhibitors; Interleukin-1beta; Maze Learning; Mice; Mucopolysaccharidosis III | 2016 |
Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.
Topics: 1-Deoxynojirimycin; Animals; Behavior, Animal; Body Weight; Brain; Cognition; Cyclodextrins; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Hypolipidemic Agents; Male; Maze Learning; Mice; Mice, Inbred BALB C; Niemann-Pick Disease, Type C; Organ Size; Pregnanolone | 2016 |
Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Dose-Response Relationship, Drug; Ebolavirus; Imino Sugars; Macaca; Marburgvirus; Mice; Models, Animal; Vero Cells | 2017 |
Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Cholesterol; Cyclodextrins; Disease Models, Animal; Disease Progression; Drug Synergism; Enzyme Inhibitors; Glycosphingolipids; Mice; Mice, Transgenic; Neurons; Niemann-Pick Disease, Type C; Pregnanolone; Treatment Outcome | 2009 |
Modulators of sphingolipid metabolism reduce lung inflammation.
Topics: 1-Deoxynojirimycin; Amitriptyline; Animals; Anti-Inflammatory Agents; Cell Line; Ceramides; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation Mediators; Interleukin-8; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Pneumonia; Pseudomonas aeruginosa; Respiratory Mucosa | 2011 |
Fusion failure of dense-cored proacrosomal vesicles in an inducible mouse model of male infertility.
Topics: 1-Deoxynojirimycin; Acrosome; Animals; Asthenozoospermia; Cell Nucleus; Disease Models, Animal; Enzyme Inhibitors; Golgi Apparatus; Male; Membrane Fusion; Mice; Secretory Vesicles; Spermatids; Spermatogenesis; Ultrasonography | 2011 |
[Report of attendance at the Parseghian Scientific Conference for Niemann-Pick Type C (NP-C) Research, South Bend, Indiana: in search of new therapeutic possibilities for a very rare illness].
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Adolescent; Animals; beta-Cyclodextrins; Child; Disease Models, Animal; Diseases in Twins; Drugs, Investigational; Histone Deacetylases; Humans; Infusions, Intravenous; Injections, Spinal; Mice; Niemann-Pick Disease, Type C; Research; United States; United States Food and Drug Administration | 2011 |
Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors.
Topics: 1-Deoxynojirimycin; Acetic Acid; Animals; Apoptosis; Disease Models, Animal; Enzyme Inhibitors; Fumonisins; G(M3) Ganglioside; Gastric Mucosa; Glucosylceramides; Glucosyltransferases; Humans; Male; Morpholines; Rats; Rats, Sprague-Dawley; Sphingolipids; Stomach Ulcer | 2013 |
Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blotting, Western; Brain; Calcium; Calcium-Transporting ATPases; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Enzyme Inhibitors; G(M2) Ganglioside; Gangliosides; Genotype; Glycolipids; Hippocampus; Kinetics; Lipid Metabolism; Mice; Mice, Transgenic; Microsomes; Neurons; Reverse Transcriptase Polymerase Chain Reaction; Sandhoff Disease; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Spectrophotometry; Thapsigargin; Time Factors | 2003 |
Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Animals; Aorta; Disease Models, Animal; Enzyme Inhibitors; Fabry Disease; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Phenotype | 2007 |
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
Topics: 1-Deoxynojirimycin; Animals; beta-Galactosidase; Brain; Disease Models, Animal; Enzyme Inhibitors; Feces; Gangliosidosis, GM1; Glucosyltransferases; Glycosphingolipids; Humans; Macrophage Activation; Mice; Mice, Knockout; Motor Activity; Protein Transport | 2008 |
N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Cells, Cultured; Disease Models, Animal; Gaucher Disease; Glucosylceramidase; Glucosyltransferases; Glycolipids; Humans; Mice; Oligosaccharides; Structure-Activity Relationship | 1994 |
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Enzyme Inhibitors; G(M2) Ganglioside; Lysosomes; Mice; Microscopy, Electron; Neurons; Tay-Sachs Disease | 1997 |
Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Topics: 1-Deoxynojirimycin; Animals; beta-N-Acetylhexosaminidases; Bone Marrow Transplantation; Brain; Diagnostic Techniques, Neurological; Disease Models, Animal; Enzyme Inhibitors; Glycosphingolipids; Hexosaminidase B; Mice; Sandhoff Disease; Spinal Cord; Survival Rate | 2001 |
Critical role for glycosphingolipids in Niemann-Pick disease type C.
Topics: 1-Deoxynojirimycin; Age Factors; Animals; Carrier Proteins; Cats; Cerebellum; Disease Models, Animal; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Glycosphingolipids; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Niemann-Pick C1 Protein; Niemann-Pick Diseases | 2001 |